CD33 and acute myeloid leukemia: Subsequent studies—ALFA-0701 [8] and MyloFrance-1 [9] in patients with CD33-positive AML in first relapse—demonstrated that fractionating the dose of GO (as 3 mg/m2 on Days 1, 4, and 7) can enhance its safety profile while maintaining efficacy.